Dalpiciclib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Hormone-Sensitive Prostate Cancer.

Abiraterone is under clinical development by Austhera BioSciences and currently in Phase II for Hormone-Sensitive Prostate Cancer.

During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes ...

Abstract: Accurately predicting the impact of hormonal therapy on Prostate Cancer (PC) lesions is paramount for effective treatment planning and monitoring. This study proposes a comprehensive ...

4, 2024 — A treatment paradox has recently come to light in prostate cancer: blocking testosterone production halts tumor growth in early disease, while elevating the hormone can delay disease ...

Discover the study supports the potential of neoadjuvant androgen deprivation therapy as an adjunctive therapy in HRLPC.

The University of Mississippi Medical Center Cancer Center and Research Institute received a $1.4 million grant from the U.S.

Cite this: The Role of Hormonal Therapy in the Management of Hormonal-Receptor-Positive Breast Cancer With Co-Expression of HER2 - Medscape - Sep 01, 2008. The article is based primarily on a ...

Sleep apnoea is a sleep disorder that causes a person to repeatedly stop or shallowly breathe while sleeping Read this ...

The study showed that adding Nubeqa to standard therapy with anti-androgen ... metastatic castration-resistant prostate cancer (CRPC), but expansion into hormone-sensitive prostate cancer could ...

Detecting breast cancer early is crucial for successful treatment and understanding the body's signals like hormonal changes plays an important role in early detection. Is your hormonal balance a ...

understanding and recognizing potential warning signs can lead to earlier detection and more effective treatment outcomes.